Lexeo Therapeutics, Inc. (LXEO)
NASDAQ: LXEO · Real-Time Price · USD
4.120
-0.060 (-1.44%)
Jun 27, 2025, 4:00 PM - Market closed
Lexeo Therapeutics Analyst Ratings
Total Analysts
5
Consensus Rating
Strong Buy
Price Target
$16.60
Upside
+302.91%
Ratings History
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
JP Morgan | JP Morgan | Buy Maintains $16 → $10 | Buy | Maintains | $16 → $10 | +142.72% | May 30, 2025 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $23 → $15 | Strong Buy | Maintains | $23 → $15 | +264.08% | May 16, 2025 |
Chardan Capital | Chardan Capital | Strong Buy Maintains $22 → $20 | Strong Buy | Maintains | $22 → $20 | +385.44% | May 13, 2025 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $23 | Strong Buy | Reiterates | $23 | +458.25% | Apr 8, 2025 |
Chardan Capital | Chardan Capital | Strong Buy Maintains $25 → $22 | Strong Buy | Maintains | $25 → $22 | +433.98% | Apr 8, 2025 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $23 | Strong Buy | Reiterates | $23 | +458.25% | Mar 26, 2025 |
Chardan Capital | Chardan Capital | Strong Buy Maintains $25 | Strong Buy | Maintains | $25 | +506.80% | Mar 25, 2025 |
RBC Capital | RBC Capital | Buy Maintains $24 → $20 | Buy | Maintains | $24 → $20 | +385.44% | Mar 25, 2025 |
Leerink Partners | Leerink Partners | Buy Maintains $19 → $18 | Buy | Maintains | $19 → $18 | +336.89% | Mar 24, 2025 |
RBC Capital | RBC Capital | Buy Reiterates $24 | Buy | Reiterates | $24 | +482.52% | Jan 21, 2025 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $21 → $23 | Strong Buy | Maintains | $21 → $23 | +458.25% | Nov 14, 2024 |
Chardan Capital | Chardan Capital | Strong Buy Maintains $23 → $25 | Strong Buy | Maintains | $23 → $25 | +506.80% | Nov 13, 2024 |
Leerink Partners | Leerink Partners | Buy Maintains $20 → $19 | Buy | Maintains | $20 → $19 | +361.17% | Nov 13, 2024 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $21 | Strong Buy | Reiterates | $21 | +409.71% | Oct 31, 2024 |
Chardan Capital | Chardan Capital | Strong Buy Maintains $23 | Strong Buy | Maintains | $23 | +458.25% | Oct 30, 2024 |
Chardan Capital | Chardan Capital | Strong Buy Maintains $23 | Strong Buy | Maintains | $23 | +458.25% | Oct 25, 2024 |
Upgrade to Pro
Get stock forecasts from Wall Street's highest rated professionals
Get much more with Stock Analysis Pro
- Investment ideas from the top Wall Street analysts
- Unlimited access to all data and tools
- Advanced analyst filtering and sorting options
- Up to 10 years of analyst rating history
Analyst Star Rankings
Our analyst star rankings are based on these four factors
- Success Rate
- The percentage of ratings that are profitable.
- Average Return
- The average percentage return within one year of the rating.
- Rating Count
- The more ratings the analyst has provided, the higher the score.
- Recency
- Ratings provided within the past year contribute to a higher score.